Hemogenyx Pharmaceuticals Plc (HEMO) Ordinary Shares 1p
0.075p
(4.92%)
- Add to watchlist
- Create an alert
- This stock can be held in a
0.075p
(4.92%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.075p
(4.92%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. It is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, with bone marrow or hematopoietic stem cell transplants, and with viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HEMO-CAR-T, is therapy for the treatment of AML in which a patient’s own T-cells, a type of immune cell, are modified to recognize and kill the patient’s cancer cells. CBR is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
Contact details
Important dates
General stock information
- EPIC:
- HEMO
- ISIN:
- GB00BYX3WZ24
- Market cap:
- £22.43 million
- Shares in issue:
- 1.40 billion
- Sector:
- Pharmaceuticals & Biotechnology
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.